Show simple item record

dc.contributor.authorCasalà, Carla
dc.contributor.authorGil-Guiñón, Estel
dc.contributor.authorOrdóñez García, José Luis 
dc.contributor.authorMiguel-Queralt, Solange
dc.contributor.authorRodríguez, Eva
dc.contributor.authorGalván, Patricia
dc.contributor.authorLavarino, Cinzia
dc.contributor.authorMunell, Francina
dc.contributor.authorde Álava Casado, Enrique
dc.contributor.authorMora, Jaume
dc.contributor.authorde Torres, Carmen
dc.date.accessioned2024-01-22T10:11:33Z
dc.date.available2024-01-22T10:11:33Z
dc.date.issued2013
dc.identifier.citationCasalà, C., Gil-Guiñón, E., Ordóñez, J. L., Miguel-Queralt, S., Rodríguez, E., Galván, P., ... & de Torres, C. (2013). The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis. Carcinogenesis, 34(2), 268-276. https://doi.org/10.1093/carcin/bgs338es_ES
dc.identifier.issn0143-3334
dc.identifier.urihttp://hdl.handle.net/10366/154479
dc.descriptionJosé Luis Ordóñez disfrutó de un contrato postdoctoral del ISCIII "Contrato Postdoctoral de Perfeccionamiento" denominado actualmente Contrato Sara Borrell. Código: CD06/00001es_ES
dc.description.abstract[EN]Neuroblastic tumors (NTs) include the neuroblastomas, ganglioneuroblastomas and ganglioneuromas. We have reported previously that the calcium-sensing receptor is expressed in differentiated, favorable NTs but almost undetectable in unfavorable neuroblastomas. We have now detected hypermethylation of a particular region within the CpG island encompassing the CaSR gene promoter 2 in neuroblastoma cell lines and 25% primary neuroblastomas. Hypermethylation of this region was associated with reduced CaSR messenger RNA expression and several predictors of poor outcome in neuroblastomas, including MYCN amplification. Treatment with 5′aza-2-deoxycitidine and/or trichostatin. A restored CaSR expression in MYCN-amplified cell lines. Following 5′aza-2-deoxycitidine exposure, decreased percentages of methylated CpG sites were observed at the above-mentioned region. By interphase fluorescence in situ hybridization, variable percentages of nuclei with monosomy of chromosome 3, where the human CaSR gene resides, were observed in more than 90% of primary NTs of all subgroups. Nuclei harboring this alteration were heterogeneously distributed among tumor cells. Ectopic overexpression of the calcium-sensing receptor in two MYCN-amplified neuroblastoma cell lines in which this gene is silenced by promoter hypermethylation significantly reduced their in vitro proliferation rates and almost abolished their capacity to generate xenografts in immunocompromised mice. Finally, upon acute exposure to calcium, the primary activator of this receptor, calcium-sensing receptor-overexpressing neuroblastoma cells underwent apoptosis, a process dependent on sustained activation of ERK1/2. These data would support the hypothesis that epigenetic silencing of the CaSR gene is neither an in vitro artefact in neuroblastoma cell lines nor an irrelevant, secondary event in primary NTs, but a significant mechanism for neuroblastoma survival.es_ES
dc.description.sponsorshipFundació Privada Cellex (CdT); Instituto de Salud Carlos III (CD6/00001 to J.L.O).es_ES
dc.format.mimetypeapplication/pdf
dc.language.isoenges_ES
dc.publisherOxford Academices_ES
dc.rightsAttribution-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nd/4.0/*
dc.subjectCARes_ES
dc.subjectEpigenéticaes_ES
dc.subjectEpigenetices_ES
dc.subjectNeuroblastomaes_ES
dc.subjectCalcium-sensing receptores_ES
dc.subjectReceptor de Calcioes_ES
dc.subject.meshEpigenetic Repression *
dc.subject.meshNeuroblastoma *
dc.titleThe calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1093/carcin/bgs338es_ES
dc.subject.unescoepigeneticaes_ES
dc.subject.unesconeuroblastomaes_ES
dc.identifier.doi10.1093/CARCIN/BGS338
dc.rights.accessRightsinfo:eu-repo/semantics/embargoedAccesses_ES
dc.identifier.essn1460-2180
dc.journal.titleCarcinogenesises_ES
dc.volume.number34es_ES
dc.issue.number2es_ES
dc.page.initial268es_ES
dc.page.final276es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsneuroblastoma *
dc.subject.decsrepresión epigenética *


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NoDerivatives 4.0 Internacional